A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
Status:
Terminated
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as
aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.
Combining hydrocortisone with either aminoglutethimide or ketoconazole may be an effective
treatment for prostate cancer.
PURPOSE: Phase II trial to study the effectiveness of combining hydrocortisone with either
aminoglutethimide or ketoconazole in treating patients who have localized stage IV prostate
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Janssen Pharmaceuticals National Cancer Institute (NCI)